Skip Page Header

Home > EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA).

European Monitoring Centre for Drugs and Drug Addiction. (2017) EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA). Luxembourg: Joint Reports, Publications Office of the European Union. 15 p.

[img]
Preview
PDF (EMCDDA–Europol Joint Report on a new psychoactive substance) - Published Version
393kB

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as ADB-CHMINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.

Item Type
Evidence resource
Publication Type
Report
Drug Type
New psychoactive substance
Date
September 2017
Pages
15 p.
Publisher
Joint Reports, Publications Office of the European Union
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
EndNote
Accession Number
HRB (Electronic Only)

Repository Staff Only: item control page